Mesupron is a selective matrix metalloproteinase-2 inhibitor classified as an anti-cancer agent, primarily investigated for its role in treating metastatic breast cancer and various solid tumors by inhibiting… Read more
Mesupron is a selective matrix metalloproteinase-2 inhibitor classified as an anti-cancer agent, primarily investigated for its role in treating metastatic breast cancer and various solid tumors by inhibiting tumor cell invasion. Laboratories rely on high-quality reference standards for this compound to ensure the accuracy and reliability of analytical testing during drug development. Stable isotope labelled compounds, such as the d8-isotopologue, are critical for internal standard usage in mass spectrometry, facilitating precise quantification in pharmacokinetic studies and biological matrix analysis. Alongside these labelled standards, related impurities and metabolites are essential for method validation, impurity profiling, and quality control assays. These analytical tools allow researchers to establish robust high-performance liquid chromatography methods necessary for characterizing the drug and its transformation products throughout preclinical and clinical research phases.